Apixaban (ELIQUIS) is an oral selective activation factor X inhibitor, jointly developed by Pfizer and Bristol-Myers Squibb. Eliquis can prevent thrombosis, but the adverse effects of bleeding are lower than that of the old drug warfarin. It is used for thrombosis prevention in patients who have undergone hip or knee replacement surgery.
Apixaban is a new type of oral anticoagulant, a new type of oral factor Xa inhibitor, and a drug used to prevent and treat blood clots. The recommended dose is 2.5 mg, taken orally twice a day, which can effectively prevent venous thromboembolism without increasing the risk of bleeding. There is no need for routine monitoring of coagulation function and no dose adjustment. Suitable for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE)
|
